Compare Microsoft (MSFT) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Microsoft vs Novartis AG — how do they compare? Microsoft trades at $534.9 (market cap $3.88T), while Novartis AG trades at $143.75 (market cap $268.57B). The key difference: Microsoft is far larger — about 14.4× Novartis AG's market cap, and Novartis AG pays the higher dividend (3.31%). Which is the better fit depends on your goals — on Pluang, investors hold Microsoft for 142 Days and Novartis AG for 82 Days on average.
| MSFT | NVS | |
|---|---|---|
Market Cap | $3.88T | $268.57B |
Volume | 19,593,392 | 1,532,573 |
Sector | Technology | Health |
52-Week High | $542.07 | $168.62 |
52-Week Low | $352.83 | $121.80 |
Typical Hold Time | 142 Days | 82 Days |
Enterprise Value | $3.86T | $309.89B |
Dividend Yield | 0.75% | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Microsoft (MSFT) trades at $535.07, up 1.0% with strong bullish technical signals and consistent earnings beats. The company demonstrates robust fundamentals with 36.1% net margins, $281.7B revenue, and healthy cash flow generation. Recent analyst coverage shows 82% buy ratings with a $571.76 consensus target, while technical indicators suggest support at $517 and resistance at $530.
MSFT presents a compelling investment case with strong AI positioning and cloud growth, though elevated valuation metrics and competitive pressures warrant caution. The stock's current level near resistance suggests potential for consolidation before further upside, supported by institutional confidence and solid financial performance.
Novartis (NVS) trades at $143.75, up 0.33% on the day, near the consensus price target of $146.00. Recent earnings show mixed quarterly beats and a miss in Q1 2026, with revenue growth to $56.67B in 2025 and a net income margin of 24.67%. Technical indicators signal a bearish trend, while analyst sentiment is mixed with 24% buy ratings. The company recently announced a $7.8B licensing deal with China's Abogen for mRNA therapy, but faces scrutiny over clinical setbacks and M&A strategy.
The outlook for NVS hinges on execution of its pipeline and deal integration amid investor caution. Opportunities include expansion into autoimmune treatments and solid profitability, but risks involve trial failures, regulatory probes, and debt levels rising to 30.26% of assets. Wall Street remains neutral with a slight upside to the price target.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Microsoft
Microsoft Corporation develops, manufactures, licenses, sells, and supports software products. The Company offers operating system software, server application software, business and consumer applications software, software development tools, and Internet and intranet software. Microsoft also develops video game consoles and digital music entertainment devices.
Read more on MSFT →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
